arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

FATE THERAPEUTICS INC

FATE
$1.85 ▼ -0.25 (-11.69%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
61 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

FATE THERAPEUTICS INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $222.7M
Dividend Yield —
Revenue Growth 9.2% ↗
Op. Margin None
ROIC -16.0% ↘
FCF / Share $-0.20 ↗
Trailing P/E —
Price / Book 1.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

61-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.08M
↑ +9.2% —
Net Income Profit after all expenses
$-31.21M
↑ +17.0% —
Operating Margin Operating profit as % of sales
-48.5%
↑ +66.6% —
FCF / Share Free cash flow per share
$-0.20
↑ +10.9% —
Long-Term Debt Long-term obligations
$10.96M
↓ -14.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
13
Cash Quality ↓
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 61 quarters